A randomized phase-II study of reirradiation and hyperthermia versus reirradiation and hyperthermia plus chemotherapy for locally recurrent breast cancer in previously irradiated area
- PMID: 35139725
- DOI: 10.1080/0284186X.2022.2033315
A randomized phase-II study of reirradiation and hyperthermia versus reirradiation and hyperthermia plus chemotherapy for locally recurrent breast cancer in previously irradiated area
Abstract
Background: In patients with inoperable local regional recurrences of breast cancer in previously irradiated areas, local control is difficult to maintain and treatment options are limited. The Dutch standard treatment for such recurrences is reirradiation combined with hyperthermia. Apart from enhancing the effect of reirradiation, hyperthermia is also known to improve local effects of chemotherapy like cisplatin. This randomized phase-II trial compares reirradiation and hyperthermia versus the same treatment combined with cisplatin.
Patients and methods: From December 2010 up to January 2019, 49 patients were randomized, 27 in the standard arm and 22 in the combined arm. A total of 32 Gy was given in eight fractions of 4 Gy in 4 weeks, at two fractions per week. After January 2015, the radiation schedule was changed to 46 Gy in 23 fractions of 2 Gy, at five fractions per week. Hyperthermia was added once a week after radiotherapy. The combined arm was treated with four cycles of weekly cisplatin 40 mg/m2.
Results: Complete response rate was 60.9% in the standard arm and 61.1% in the combined arm (p = 0.87). Partial response rate was 30.4% in the standard arm and 33.3% in the combined arm (p = 0.79). One-year overall survival was 63.4% in the standard arm and 57.4% in the combined arm. One-year local progression-free interval was 81.5% in the standard arm and 88.1% in the combined arm (p = 0.95). Twenty-five percentage of patients in the standard arm experienced grade 3 or 4 acute toxicity and 29% of patients in the combined arm (p = 0.79).
Conclusion: No potential benefit could be detected of adding cisplatin to reirradiation and hyperthermia in patients with recurrent breast cancer in a previously irradiated area. With or without cisplatin, most patients had subsequent local control until last follow-up or death.
Keywords: Hyperthermia; cisplatin; recurrent breast cancer; reirradiation.
Similar articles
-
Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: Size matters.Radiother Oncol. 2015 Nov;117(2):223-8. doi: 10.1016/j.radonc.2015.10.017. Epub 2015 Nov 2. Radiother Oncol. 2015. PMID: 26542015
-
Rib fractures after reirradiation plus hyperthermia for recurrent breast cancer: Predictive factors.Strahlenther Onkol. 2016 Apr;192(4):240-7. doi: 10.1007/s00066-016-0946-3. Epub 2016 Feb 8. Strahlenther Onkol. 2016. PMID: 26856858 Free PMC article.
-
Reirradiation + hyperthermia for recurrent breast cancer en cuirasse.Strahlenther Onkol. 2018 Mar;194(3):206-214. doi: 10.1007/s00066-017-1241-7. Epub 2017 Dec 20. Strahlenther Onkol. 2018. PMID: 29264624 Free PMC article.
-
[Re-irradiation with hyperthermia in patients with recurrent breast cancer].Ned Tijdschr Geneeskd. 1999 Jan 9;143(2):80-4. Ned Tijdschr Geneeskd. 1999. PMID: 10086109 Review. Dutch.
-
Reirradiation for locally recurrent breast cancer.Breast. 2017 Jun;33:159-165. doi: 10.1016/j.breast.2017.03.008. Epub 2017 Apr 7. Breast. 2017. PMID: 28395234 Review.
Cited by
-
The Effect of Hyperthermia and Radiotherapy Sequence on Cancer Cell Death and the Immune Phenotype of Breast Cancer Cells.Cancers (Basel). 2022 Apr 19;14(9):2050. doi: 10.3390/cancers14092050. Cancers (Basel). 2022. PMID: 35565180 Free PMC article.
-
Prospective randomized clinical studies involving reirradiation: update of a systematic review.Strahlenther Onkol. 2023 Sep;199(9):787-797. doi: 10.1007/s00066-023-02118-1. Epub 2023 Jul 27. Strahlenther Onkol. 2023. PMID: 37500926 Free PMC article.
-
Innovative therapeutic strategies to overcome radioresistance in breast cancer.Front Oncol. 2024 May 30;14:1379986. doi: 10.3389/fonc.2024.1379986. eCollection 2024. Front Oncol. 2024. PMID: 38873260 Free PMC article. Review.
-
Tolerance and Oncological Outcomes of In-Field Reirradiation for Locally Recurrent Breast Cancer: A Long-Term Single-Center Experience.Cancers (Basel). 2023 Sep 12;15(18):4515. doi: 10.3390/cancers15184515. Cancers (Basel). 2023. PMID: 37760484 Free PMC article.
-
How Magnetic Composites are Effective Anticancer Therapeutics? A Comprehensive Review of the Literature.Int J Nanomedicine. 2023 Jun 30;18:3535-3575. doi: 10.2147/IJN.S375964. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37409027 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical